Vertex Expects Shorter Duration Of Therapy Will Give Telaprevir Long Reign Atop Market
This article was originally published in The Pink Sheet Daily
Executive Summary
With high SVR rate and quad therapy showing potential for 12-week treatment period, telaprevir may enjoy short- and long-term market success.